Treatment of prostatic cancer. Newer forms of androgen deprivation.
The hope of providing a safe alternative to bilateral orchiectomy for patients with prostatic cancer has spurred the development in recent years of various agents capable of reducing androgen level. Another reason for intensifying these efforts relates to the hope held by many clinicians that earlier initiation of androgen deprivation for patients with regional or distant metastases will improve the patient's course. Finally, attempts to provide a more complete androgen blockade hold the hope of delaying or preventing relapse, which usually occurs with continued androgen deprivation.
D000726:Androgen Antagonists / Q000627:therapeutic use*; D003534:Cyproterone / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D017373:Cyproterone Acetate; D005485:Flutamide / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008535:Megestrol / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D019290:Megestrol Acetate; D009362:Neoplasm Metastasis; D009919:Orchiectomy; D010906:Pituitary Hormone-Releasing Hormones / Q000009:adverse effects / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000601:surgery
D000726:Androgen Antagonists; D010906:Pituitary Hormone-Releasing Hormones; D017373:Cyproterone Acetate; D005485:Flutamide; D003534:Cyproterone; D008535:Megestrol; D019290:Megestrol Acetate